Neuropace (NPCE) vs Profound Medical (PROF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Profound Medical (PROF) has outperformed Neuropace (NPCE) over the past year, gaining 6.2% versus a loss of 44.6%. Over five years, NPCE leads with a -32.8% price change compared with -43.6% for PROF. Neuropace is the larger company by market cap ($273.9 million vs $233.7 million), about 1.2 times the size, while Profound Medical is growing revenue faster (+50.7% vs +25.1%).
Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -264.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NPCE | PROF |
|---|---|---|
| Share price | $7.95 | $6.38 |
| Market cap | $273.89M | $233.68M |
| 1-day change | -2.33% | -3.19% |
| YTD return | -48.51% | -18.93% |
| 1-year return | -44.60% | +6.16% |
| 5-year return | -32.80% | -43.64% |
| EPS (TTM) | $-0.56 | $-0.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $99.99M | $16.10M |
| Revenue growth (YoY) | +25.13% | +50.73% |
| Net income (latest FY) | $-21.46M | $-42.57M |
| Gross margin | 77.23% | 70.77% |
| Operating margin | -16.34% | -256.27% |
| Net margin | -21.47% | -264.44% |
| 52-week high | $19.60 | $8.95 |
| 52-week low | $5.46 | $4.80 |
| Distance from 52-week high | -59.44% | -28.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +53.71% | +74.61% |
| Average volume | 270.76K | 208.29K |
| Shares outstanding | 34.45M | 36.63M |
| Employees | 216 | 162 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PROF has outperformed NPCE by 50.8 percentage points over the past year.
- Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
- Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +25.13%).
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 216 employees
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
NPCE vs PROF FAQ
Which is bigger, Neuropace or Profound Medical?
Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $233.68M for Profound Medical (PROF).
Which stock has performed better over the past year, NPCE or PROF?
PROF returned +6.16% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.
Are Neuropace and Profound Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.